ALX Oncology Holdings, Inc. (ALXO)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about ALX Oncology Holdings, Inc. (ALXO)
Go deeper and ask any question about ALXO
Company Performance
Current Price
as of Sep 17, 2024$2.18
P/E Ratio
N/A
Market Cap
$114.82M
Description
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
Metrics
Overview
- HQSouth San Francisco, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerALXO
- Price$2.180.00%
Trading Information
- Market Cap$114.82M
- Float57.36%
- Average Daily Volume (1m)632,908
- Average Daily Volume (3m)1,281,602
- EPS-$3.64
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$39.40M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$41.31M
- EV$173.29M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account